Skip to main content

NTLA Competitors

profileAnalyst coverage5 yr. financialspremium researchdividendsadv. chartsearningsoptionsprice historyeventsinsiders

Intellia Therapeutics Inc. News

Alnylam's 5th Drug Launches in July, Disrupting Commercial Landscape

A little competition can greatly benefit patients. Shareholders may have a more difficult path to navigate.

Cramer's Mad Money Recap 2/1: Colgate-Palmolive, Stanley Black & Decker

Jim Cramer says stocks are caught between the forces of inflation and deflation, and investors need to find companies that can adapt.

Cathie Wood as Counter Indicator? Crispr Stumbles

Cathie Wood's Ark Investment bought shares of Germany’s Crispr Tuesday, a media report says. The stock slid on Wednesday.

Intellia Stock Jumps on Progress With Gene-Editing Treatment

'These data open a new era of medicine – one that holds the potential of curing genetic disease,' Intellia said. Its shares are higher.

Intellia Therapeutics Leads Gene-Editing Stock Rally

Intellia Therapeutics rises and other gene-editing stocks follow suit.

Breaking News

Elon Musk Says Only Two Things Could Make Him Leave Tesla

Tesla CEO Musk discusses succession plans and Twitter with shareholders.

Caesars Inches Closer to Huge Las Vegas Strip Move

The company has made clear what it plans on the Las Vegas Strip, but it has a fast-approaching deadline.

Elon Musk Has Bad News About Tesla's Cybertruck

Long-delayed futuristic looking electric vehicle will be in production by the middle of 2023